Roche Holding AG Price to Sales Ratio 2010-2023 | RHHBY

Historical PS ratio values for Roche Holding AG (RHHBY) over the last 10 years. The current P/S ratio for Roche Holding AG as of January 20, 2025 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Roche Holding AG P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
0.00 nan
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $231.838B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.937B 71.36
Johnson & Johnson (JNJ) United States $353.993B 14.36
Novo Nordisk (NVO) Denmark $353.124B 25.47
AbbVie (ABBV) United States $303.171B 15.96
Merck (MRK) United States $247.702B 16.46
AstraZeneca (AZN) United Kingdom $206.533B 17.57
Novartis AG (NVS) Switzerland $199.351B 13.25
Pfizer (PFE) United States $149.042B 10.19
Sanofi (SNY) $128.770B 11.66
Bayer (BAYRY) Germany $21.338B 3.42
Innoviva (INVA) United States $1.163B 9.68